Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Biogen buys Remedy Pharmaceuticals' stroke drug Cirara

Biogen will pay $120 mn upfront payment plus potential milestone and royalty payments

BS B2B Bureau  |  Cambridge, Massachusetts 

Biogen lab

last week completed an asset purchase of Remedy Pharmaceuticals’ phase 3 candidate, (intravenous glyburide). Under the terms of the agreement, Remedy will share in the cost of development for the target indication for in LHI stroke. will make an upfront payment of $120 million to Remedy and may also pay additional milestone payments and royalties. 

The target indication for is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted Fast Track designation. 

Each year approximately 1.7 million ischemic strokes occur across the US, Europe and Japan, and approximately 15 percent of these are LHI strokes. In pre-clinical studies, has been shown to block SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical proof-of-concept studies have demonstrated the potential of to reduce brain swelling, disability and the risk of death in patients with LHI. 

“Building on our leading position in multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease research, we see a compelling opportunity in stroke where we can leverage our core expertise in neuroscience to make a major difference in patient care. represents a potential breakthrough stroke treatment that accelerates our efforts to build a portfolio of new therapies for neurologic diseases. We believe the data supporting the potential of are compelling and that can be a first-in-class therapy that gives physicians the ability to meaningfully improve patient outcomes in an area where effective treatments have been few and far between,” said Michael Ehlers, executive vice president, research and development at

This transaction complements Biogen’s broader efforts to build a portfolio of best-in-class treatments for acute ischemic stroke and further strengthen its leadership in neuroscience. currently is conducting a phase 2b study to determine whether its monoclonal antibody natalizumab can help patients with acute ischemic stroke improve functional outcomes by limiting brain inflammation in the post-stroke period. If successful, natalizumab and will provide new approaches to treating different populations of stroke patients.

RECOMMENDED FOR YOU

Biogen buys Remedy Pharmaceuticals' stroke drug Cirara

Biogen will pay $120 mn upfront payment plus potential milestone and royalty payments

Biogen will pay $120 mn upfront payment plus potential milestone and royalty payments
last week completed an asset purchase of Remedy Pharmaceuticals’ phase 3 candidate, (intravenous glyburide). Under the terms of the agreement, Remedy will share in the cost of development for the target indication for in LHI stroke. will make an upfront payment of $120 million to Remedy and may also pay additional milestone payments and royalties. 

The target indication for is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted Fast Track designation. 

Each year approximately 1.7 million ischemic strokes occur across the US, Europe and Japan, and approximately 15 percent of these are LHI strokes. In pre-clinical studies, has been shown to block SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical proof-of-concept studies have demonstrated the potential of to reduce brain swelling, disability and the risk of death in patients with LHI. 

“Building on our leading position in multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease research, we see a compelling opportunity in stroke where we can leverage our core expertise in neuroscience to make a major difference in patient care. represents a potential breakthrough stroke treatment that accelerates our efforts to build a portfolio of new therapies for neurologic diseases. We believe the data supporting the potential of are compelling and that can be a first-in-class therapy that gives physicians the ability to meaningfully improve patient outcomes in an area where effective treatments have been few and far between,” said Michael Ehlers, executive vice president, research and development at

This transaction complements Biogen’s broader efforts to build a portfolio of best-in-class treatments for acute ischemic stroke and further strengthen its leadership in neuroscience. currently is conducting a phase 2b study to determine whether its monoclonal antibody natalizumab can help patients with acute ischemic stroke improve functional outcomes by limiting brain inflammation in the post-stroke period. If successful, natalizumab and will provide new approaches to treating different populations of stroke patients.

image
Business Standard
177 22

Biogen buys Remedy Pharmaceuticals' stroke drug Cirara

Biogen will pay $120 mn upfront payment plus potential milestone and royalty payments

last week completed an asset purchase of Remedy Pharmaceuticals’ phase 3 candidate, (intravenous glyburide). Under the terms of the agreement, Remedy will share in the cost of development for the target indication for in LHI stroke. will make an upfront payment of $120 million to Remedy and may also pay additional milestone payments and royalties. 

The target indication for is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality. The US Food and Drug Administration (FDA) recently granted Orphan Drug Designation for severe cerebral edema in patients with acute ischemic stroke. The FDA has also granted Fast Track designation. 

Each year approximately 1.7 million ischemic strokes occur across the US, Europe and Japan, and approximately 15 percent of these are LHI strokes. In pre-clinical studies, has been shown to block SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical proof-of-concept studies have demonstrated the potential of to reduce brain swelling, disability and the risk of death in patients with LHI. 

“Building on our leading position in multiple sclerosis, spinal muscular atrophy, and Alzheimer’s disease research, we see a compelling opportunity in stroke where we can leverage our core expertise in neuroscience to make a major difference in patient care. represents a potential breakthrough stroke treatment that accelerates our efforts to build a portfolio of new therapies for neurologic diseases. We believe the data supporting the potential of are compelling and that can be a first-in-class therapy that gives physicians the ability to meaningfully improve patient outcomes in an area where effective treatments have been few and far between,” said Michael Ehlers, executive vice president, research and development at

This transaction complements Biogen’s broader efforts to build a portfolio of best-in-class treatments for acute ischemic stroke and further strengthen its leadership in neuroscience. currently is conducting a phase 2b study to determine whether its monoclonal antibody natalizumab can help patients with acute ischemic stroke improve functional outcomes by limiting brain inflammation in the post-stroke period. If successful, natalizumab and will provide new approaches to treating different populations of stroke patients.

image
Business Standard
177 22